Cost, effect and net benefit for all the included strategies for a cohort of 100 000 subjects invited for screening
| No screening | Aspirin | Sigmoidoscopy | Sigmoidoscopy and aspirin | Colonoscopy | Colonoscopy and aspirin | |
| CRC cases (n) | 5903 | 3858 | 4078 | 2487 | 1759 | 1105 |
| CRC prevented (n) | – | 2045 | 1824 | 3415 | 4014 | 4605 |
| CRC prevention rate (%) | – | 35 | 31 | 58 | 68 | 78 |
| CRC deaths (n) | 2482 | 1458 | 1503 | 779 | 803 | 477 |
| CRC death prevention rate (%) | – | 41 | 39 | 69 | 68 | 81 |
| Life-years gained (n) | – | 6232 | 7945 | 12 215 | 13 922 | 15 108 |
| Gain in life expectancy per person (days) | – | 23 | 29 | 45 | 51 | 55 |
| Screening cost (US$ per person) | – | 299 | 1293 | 1596 | 2486 | 2788 |
| Care for CRC (US$ per person) | 2227 | 1492 | 1524 | 944 | 619 | 381 |
| Total (US$ per person) | 2227 | 1791 | 2817 | 2540 | 3105 | 3169 |
| ICER vs no screening (US$ per life-year gained) | – | Dominates (saving US$436 per person)* | 7434 | 6511 | 6307 | 6237 |
↵* When a strategy was more effective and less costly than no screening (no screening being dominated), saving per person instead of the ICER was provided.
CRC, colorectal cancer; ICER, incremental cost-effectiveness ratio.